Mirae Asset Global Investments
CRSP icon

Mirae Asset Global Investments’s CRISPR Therapeutics CRSP Stock Holding History

Mirae Asset Global Investments’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$235K Sell
4,314
-693
-14% -$36.5K ﹤0.01% 1096
2026
Q1 		$238K Buy
5,007
+376
+8% +$19.8K ﹤0.01% 1057
2025
Q4 		$243K Buy
4,631
+1,115
+32% +$66.8K ﹤0.01% 1116
2025
Q3 		$228K Buy
3,516
+180
+5% +$10.3K ﹤0.01% 1112
2025
Q2 		$162K Buy
3,336
+519
+18% +$20.1K ﹤0.01% 1075
2025
Q1 		$104K Sell
2,817
-27
-0.9% -$1.15K ﹤0.01% 1122
2024
Q4 		$114K Sell
2,844
-236
-8% -$11.1K ﹤0.01% 1128
2024
Q3 		$146K Buy
3,080
+545
+21% +$27.7K ﹤0.01% 1139
2024
Q2 		$140K Sell
2,535
-164,011
-98% -$9.49M ﹤0.01% 1097
2024
Q1 		$7.45M Buy
166,546
+77,053
+86% +$5.52M 0.02% 760
2023
Q4 		$5.6M Sell
89,493
-95,361
-52% -$5.27M 0.01% 859
2023
Q3 		$8.39M Buy
184,854
+17,258
+10% +$891K 0.02% 683
2023
Q2 		$9.41M Sell
167,596
-3,571
-2% -$203K 0.02% 675
2023
Q1 		$7.74M Buy
171,167
+7,565
+5% +$367K 0.02% 736
2022
Q4 		$6.65M Sell
163,602
-5,173
-3% -$274K 0.02% 737
2022
Q3 		$11M Buy
168,775
+20,829
+14% +$1.51M 0.03% 548
2022
Q2 		$8.99M Buy
147,946
+42,564
+40% +$2.5M 0.02% 637
2022
Q1 		$6.62M Sell
105,382
-19,095
-15% -$1.2M 0.01% 787
2021
Q4 		$9.43M Buy
124,477
+35,829
+40% +$3.13M 0.02% 696
2021
Q3 		$9.92M Buy
88,648
+17,119
+24% +$2.15M 0.03% 650
2021
Q2 		$11.6M Buy
71,529
+47
+0.1% +$5.72K 0.03% 578
2021
Q1 		$8.71M Buy
71,482
+32,015
+81% +$4.83M 0.03% 574
2020
Q4 		$6.04M Buy
39,467
+381
+1% +$45K 0.02% 612
2020
Q3 		$3.27M Buy
39,086
+12,506
+47% +$1.11M 0.02% 642
2020
Q2 		$1.95M Buy
26,580
+14,309
+117% +$837K 0.01% 707
2020
Q1 		$520K Buy
12,271
+1,317
+12% +$68K ﹤0.01% 1013
2019
Q4 		$667K Buy
10,954
+1,690
+18% +$92.3K ﹤0.01% 1110
2019
Q3 		$380K Buy
+9,264
New +$443K ﹤0.01% 1246

Other funds holding CRSP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $46.3B AUM 43.9% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Mirae Asset Global Investments's CRSP Position: Q2 2026 in Review

Mirae Asset Global Investments reduced its CRISPR Therapeutics (CRSP) stake by 14% in Q2 2026, selling an estimated $36.5K and leaving 4,314 shares worth $235K. The position accounts for ﹤0.01% of the portfolio, ranked #1096.

Mirae Asset Global Investments first reported a position in CRSP in Q3 2019 and has held it in 28 quarters since. The position peaked at $11.6M in Q2 2021. 262 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Mirae Asset Global Investments held 4,314 shares of CRISPR Therapeutics worth $235K as of Q2 2026.
  • Mirae Asset Global Investments sold 693 CRISPR Therapeutics shares in Q2 2026, an estimated $36.5K.
  • CRISPR Therapeutics made up ﹤0.01% of Mirae Asset Global Investments's portfolio in Q2 2026, its #1096 holding.
  • Mirae Asset Global Investments first reported a position in CRISPR Therapeutics in Q3 2019 and has held it in 28 quarters since.
  • Mirae Asset Global Investments's CRISPR Therapeutics position peaked at $11.6M in Q2 2021.
  • 262 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Mirae Asset Global Investments's 13F filing for Q2 2026, filed 22 Jul 2026.